CMV Infection Post Allogeneic Hematopoietic Stem Cell Transplantation in a Resource Limited Country.

IF 0.7 4区 医学 Q4 HEMATOLOGY
Noor Yuhyi Sulaiman, Nur Adila Anuar, Normala Arshad, Chin Sum Cheong, Chee Chiat Liong, Shasha Khairullah, Edmund Fui Min Chin, Ping Chong Bee, I Ching Sam, Thevambiga Iyadorai, Gin Gin Gan
{"title":"CMV Infection Post Allogeneic Hematopoietic Stem Cell Transplantation in a Resource Limited Country.","authors":"Noor Yuhyi Sulaiman, Nur Adila Anuar, Normala Arshad, Chin Sum Cheong, Chee Chiat Liong, Shasha Khairullah, Edmund Fui Min Chin, Ping Chong Bee, I Ching Sam, Thevambiga Iyadorai, Gin Gin Gan","doi":"10.1007/s12288-023-01655-0","DOIUrl":null,"url":null,"abstract":"<p><p>Cytomegalovirus (CMV) infection is one of the common complications which can lead to significant morbidity and mortality in patients after allogeneic hematopoietic stem cell transplantation (HSCT). As the seroprevalence of CMV infection in Malaysia is high, this study aims to determine the prevalence of CMV infection in patients post HSCT and to evaluate the associated risk factors. Patients who underwent allogeneic HSCT in adult ward from 2008 to 2020 at a tertiary teaching hospital in Kuala Lumpur, Malaysia were studied retrospectively. They were followed up for a minimum of 100 days post-HSCT to determine the incidence of CMV infection. CMV infection was defined according to CMV Drug Development Forum 2014. Risk factors such as type of transplant, serostatus of donor and patients, age, gender, race, presence of graft versus host disease (GVHD) and underlying disease were included for analysis. A total of 112 patients were included. Forty (35.7%) patients had CMV infection with median of onset recorded as 40 days (range 13-95 days). Only haplo-identical HSCT and presence of GVHD were identified as significant risk factors. Patients who had CMV infection had a lower median survival time although this was not statistically significant. The CMV infection rate was comparable with previous reports in Asia and as expected, higher than the western countries. Therefore, vigilant monitoring of CMV infection should be implemented especially in patients who had haplo-identical HSCT and acute GVHD.</p>","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10830936/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Hematology and Blood Transfusion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12288-023-01655-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/4/20 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Cytomegalovirus (CMV) infection is one of the common complications which can lead to significant morbidity and mortality in patients after allogeneic hematopoietic stem cell transplantation (HSCT). As the seroprevalence of CMV infection in Malaysia is high, this study aims to determine the prevalence of CMV infection in patients post HSCT and to evaluate the associated risk factors. Patients who underwent allogeneic HSCT in adult ward from 2008 to 2020 at a tertiary teaching hospital in Kuala Lumpur, Malaysia were studied retrospectively. They were followed up for a minimum of 100 days post-HSCT to determine the incidence of CMV infection. CMV infection was defined according to CMV Drug Development Forum 2014. Risk factors such as type of transplant, serostatus of donor and patients, age, gender, race, presence of graft versus host disease (GVHD) and underlying disease were included for analysis. A total of 112 patients were included. Forty (35.7%) patients had CMV infection with median of onset recorded as 40 days (range 13-95 days). Only haplo-identical HSCT and presence of GVHD were identified as significant risk factors. Patients who had CMV infection had a lower median survival time although this was not statistically significant. The CMV infection rate was comparable with previous reports in Asia and as expected, higher than the western countries. Therefore, vigilant monitoring of CMV infection should be implemented especially in patients who had haplo-identical HSCT and acute GVHD.

Abstract Image

资源有限国家同种异体造血干细胞移植后巨细胞病毒感染
巨细胞病毒(CMV)感染是异基因造血干细胞移植(HSCT)后常见的并发症之一,可导致患者严重的发病率和死亡率。由于马来西亚的CMV感染血清阳性率较高,本研究旨在确定造血干细胞移植后患者的CMV感染率,并评估相关风险因素。本研究对 2008 年至 2020 年期间在马来西亚吉隆坡一家三级教学医院成人病房接受异基因造血干细胞移植的患者进行了回顾性研究。他们在造血干细胞移植后接受了至少 100 天的随访,以确定 CMV 感染的发生率。CMV感染是根据《2014年CMV药物开发论坛》定义的。风险因素包括移植类型、供体和患者的血清状态、年龄、性别、种族、是否存在移植物抗宿主疾病(GVHD)以及基础疾病等。共纳入 112 名患者。40名患者(35.7%)感染了CMV,中位发病时间为40天(13-95天不等)。只有单倍体同种造血干细胞移植和存在 GVHD 才是重要的风险因素。CMV感染患者的中位生存时间较短,但无统计学意义。CMV感染率与之前在亚洲的报告相当,正如预期的那样,高于西方国家。因此,应警惕CMV感染,尤其是单倍体同种造血干细胞移植和急性GVHD患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.70
自引率
0.00%
发文量
82
审稿时长
>12 weeks
期刊介绍: Indian Journal of Hematology and Blood Transfusion is a medium for propagating and exchanging ideas within the medical community. It publishes peer-reviewed articles on a variety of aspects of clinical hematology, laboratory hematology and hemato-oncology. The journal exists to encourage scientific investigation in the study of blood in health and in disease; to promote and foster the exchange and diffusion of knowledge relating to blood and blood-forming tissues; and to provide a forum for discussion of hematological subjects on a national scale. The Journal is the official publication of The Indian Society of Hematology & Blood Transfusion.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信